Pipeline

Accelerated clinical development, enabled by global collaborations

These networks have granted us access to large-scale GMP cell manufacturing facilities and reaching out to patients from diverse backgrounds.

BioSyngen has partnered with an extensive hospital network as well as received support from both the public sector and private enterprises in China and Singapore.

Multiple assets in pre-clinical and clinical development

PRODUCT

INDICATIONS

 PRE-CLINICAL

          IIT

    PHASE 1/     PHASE 2

BRG01

First-in-Class

Nasopharyngeal cancer

EBV+ Hematologic malignancies



BST02

Best-in-Class

Liver cancer(all types)



BRL03

First-in-Class

Multiple solid tumors (incl. Lung)



BGT007

First-in-Class

CRC, GC, EC&PDAC



Multi-specific antibodies

First-in-Class

Multiple solid tumors



Allo-cel

First-in-Class

Multiple solid and liquid tumors



Multiple assets in pre-clinical and clinical development

BRG01

First-in-Class

Nasopharyngeal cancer

 PRE-CLINICAL

          IIT

    PHASE 1/     PHASE 2

EBV+ Hematologic malignancies

 PRE-CLINICAL

          IIT

    PHASE 1/     PHASE 2

BST02

Best-in-Class

Liver cancer(all types)

 PRE-CLINICAL

          IIT

    PHASE 1/     PHASE 2

BRL03

First-in-Class

Multiple solid tumors (incl. Lung)

 PRE-CLINICAL

          IIT

    PHASE 1/     PHASE 2

BGT007

First-in-Class

CRC, GC, EC&PDAC

 PRE-CLINICAL

          IIT

    PHASE 1/     PHASE 2

Multi-specific antibodies

First-in-Class

Multiple solid tumors

 PRE-CLINICAL

          IIT

    PHASE 1/     PHASE 2

Allo-cel

First-in-Class

Multiple solid and liquid tumors

 PRE-CLINICAL

          IIT

    PHASE 1/     PHASE 2

WORK WITH US

Take part in our mission to deliver more effective cancer care and improve patient outcomes.

MENU